ATE409176T1 - 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen - Google Patents

1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen

Info

Publication number
ATE409176T1
ATE409176T1 AT04712483T AT04712483T ATE409176T1 AT E409176 T1 ATE409176 T1 AT E409176T1 AT 04712483 T AT04712483 T AT 04712483T AT 04712483 T AT04712483 T AT 04712483T AT E409176 T1 ATE409176 T1 AT E409176T1
Authority
AT
Austria
Prior art keywords
treatment
acid derivatives
neurodegenerative diseases
phenylalkanecarboxylic acid
phenylalkanecarboxylic
Prior art date
Application number
AT04712483T
Other languages
English (en)
Inventor
Luca Raveglia
Ilaria Peretto
Stefano Radaelli
Bruno Imbimbo
Andrea Rizzi
Gino Villetti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20030311 external-priority patent/ITMI20030311A1/it
Priority claimed from ITMI20032068 external-priority patent/ITMI20032068A1/it
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of ATE409176T1 publication Critical patent/ATE409176T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C07C15/12—Polycyclic non-condensed hydrocarbons
    • C07C15/14—Polycyclic non-condensed hydrocarbons all phenyl groups being directly linked
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/65—Halogen-containing esters of unsaturated acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/62—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/40—Unsaturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
AT04712483T 2003-02-21 2004-02-19 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen ATE409176T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20030311 ITMI20030311A1 (it) 2003-02-21 2003-02-21 Acidi 2-fenil-2-dialchil-acetici per il trattamento della malattia di alzheimer.
ITMI20032068 ITMI20032068A1 (it) 2003-10-23 2003-10-23 Derivati dell'acido 1-fenilcicloalcancarbossilico per il trattamento delle malattie neurodegenerative.

Publications (1)

Publication Number Publication Date
ATE409176T1 true ATE409176T1 (de) 2008-10-15

Family

ID=32910543

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04712483T ATE409176T1 (de) 2003-02-21 2004-02-19 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen

Country Status (16)

Country Link
US (3) US7662995B2 (de)
EP (1) EP1594833B1 (de)
JP (1) JP4472691B2 (de)
KR (2) KR101088272B1 (de)
AT (1) ATE409176T1 (de)
AU (1) AU2004213145B2 (de)
BR (1) BRPI0407662B8 (de)
CA (1) CA2514384C (de)
CY (1) CY1108514T1 (de)
DE (1) DE602004016729D1 (de)
DK (1) DK1594833T3 (de)
ES (1) ES2312964T3 (de)
NO (1) NO333118B1 (de)
PT (1) PT1594833E (de)
SI (1) SI1594833T1 (de)
WO (1) WO2004074232A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
EP1603548A4 (de) * 2003-02-05 2007-10-10 Myriad Genetics Inc Verfahren und zusammensetzung zur behandlung neurodegenerativer erkrankungen
SI1594833T1 (sl) * 2003-02-21 2008-12-31 Chiesi Farma Spa Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
DE602005007912D1 (de) 2004-08-03 2008-08-14 Chiesi Farma Spa Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
EP1909777A2 (de) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. Formulierungen und dosierformen mit hoherarzneibeladung
EP2046119A2 (de) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Behandlung von psychiatrischen störungen
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
US8217064B2 (en) 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
EP2133322A1 (de) * 2008-06-11 2009-12-16 CHIESI FARMACEUTICI S.p.A. Verfahren zur Herstellung von Derivaten aus 1-(2-Halobiphenyl-4-yl)-Cyclopopancarboxy-Säure
HRP20140032T1 (hr) * 2009-08-04 2014-02-14 Chiesi Farmaceutici S.P.A. Postupak priprave derivata 1-(2-halobifenil-4-il)-ciklopropankarboksilne kiseline
MX336742B (es) 2010-02-03 2016-01-29 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso.
CN106431900A (zh) * 2010-04-01 2017-02-22 奇斯药制品公司 新的多晶型物和盐
EP2560942B1 (de) 2010-04-21 2014-11-26 Chiesi Farmaceutici S.p.A. 1-(2-fluorbiphenyl-4-yl)-alkyl-carboxylsäure-derivate zur therapie von transthyretin-amyloidose
RU2012151850A (ru) 2010-06-04 2014-07-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 1-(2-фторбифенил-4-ил)циклопропанкарбоновой кислоты для терапии прионных болезней
US9592210B2 (en) 2011-12-22 2017-03-14 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment
EP2834214A1 (de) * 2012-04-04 2015-02-11 Chiesi Farmaceutici S.p.A. Derivate von 1-(2-halo-biphenyl-4-yl)-alkancarbonsäuren zur behandlung von neurodegenerativen erkrankungen
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2970177A1 (de) 2013-03-15 2016-01-20 Pfizer Inc. Indolverbindungen zur ampk-aktivierung
EP2818460A1 (de) 2013-06-24 2014-12-31 ZaCh System S.p.A. Cyclopropanation von substituierten Phenylacetonitrilen oder Phenylacetaten
CN105658615A (zh) 2013-06-24 2016-06-08 奇斯药制品公司 用于制备1-(2-氟[1,1′-联苯]-4-基)-环丙烷甲酸衍生物的改进方法
WO2015109109A1 (en) 2014-01-15 2015-07-23 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof
US20150320706A1 (en) 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
US20150335596A1 (en) 2014-05-26 2015-11-26 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the treatment of down's syndrome
US9802927B2 (en) 2015-06-10 2017-10-31 Denali Therapeutics, Inc. Oxadiazine compounds and methods of use thereof
KR20240054333A (ko) 2021-08-31 2024-04-25 세레스파이어 인코포레이티드 공결정

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1933985A1 (de) * 1968-07-04 1970-01-15 Takeda Chemical Industries Ltd Neue Cycloalkancarbonsaeurederivate und Verfahren zu ihrer Herstellung
JPS4994680A (de) 1973-01-22 1974-09-09
JPS5046669A (de) 1973-03-28 1975-04-25
JPS58177977A (ja) 1982-04-09 1983-10-18 Grelan Pharmaceut Co Ltd ４−フエニルピラゾ−ル類
AU2936295A (en) * 1994-07-13 1996-02-16 Taisho Pharmaceutical Co., Ltd. Thiopheneacetic acid derivative
JPH0994680A (ja) * 1995-07-24 1997-04-08 Toyota Motor Corp 摩擦圧接装置
US5994379A (en) 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
CA2406383A1 (en) 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
JP2006517925A (ja) * 2003-01-14 2006-08-03 メルク　エンド　カムパニー　インコーポレーテッド Ａβ４２低下薬としてのジェミナル二置換ＮＳＡＩＤ誘導体
SI1594833T1 (sl) * 2003-02-21 2008-12-31 Chiesi Farma Spa Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni
DE602005007912D1 (de) 2004-08-03 2008-08-14 Chiesi Farma Spa Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
EP2133322A1 (de) * 2008-06-11 2009-12-16 CHIESI FARMACEUTICI S.p.A. Verfahren zur Herstellung von Derivaten aus 1-(2-Halobiphenyl-4-yl)-Cyclopopancarboxy-Säure

Also Published As

Publication number Publication date
BRPI0407662B8 (pt) 2021-05-25
US20070060752A1 (en) 2007-03-15
US8314268B2 (en) 2012-11-20
EP1594833A1 (de) 2005-11-16
EP1594833B1 (de) 2008-09-24
WO2004074232A1 (en) 2004-09-02
KR20050104369A (ko) 2005-11-02
CA2514384A1 (en) 2004-09-02
NO333118B1 (no) 2013-03-04
US8022250B2 (en) 2011-09-20
NO20053855D0 (no) 2005-08-18
AU2004213145B2 (en) 2010-05-13
BRPI0407662A (pt) 2006-03-01
CA2514384C (en) 2012-04-10
HK1087398A1 (zh) 2006-10-13
NO20053855L (no) 2005-11-21
AU2004213145A1 (en) 2004-09-02
US7662995B2 (en) 2010-02-16
JP2006518351A (ja) 2006-08-10
DE602004016729D1 (de) 2008-11-06
KR20110057227A (ko) 2011-05-31
ES2312964T3 (es) 2009-03-01
KR101088272B1 (ko) 2011-11-30
WO2004074232A8 (en) 2005-09-09
US20110288175A1 (en) 2011-11-24
CY1108514T1 (el) 2014-04-09
KR101152448B1 (ko) 2012-07-02
JP4472691B2 (ja) 2010-06-02
DK1594833T3 (da) 2008-12-15
SI1594833T1 (sl) 2008-12-31
PT1594833E (pt) 2008-12-03
US20100099768A1 (en) 2010-04-22
BRPI0407662B1 (pt) 2019-11-12

Similar Documents

Publication Publication Date Title
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
EP1562897A4 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
NO20076405L (no) Anvendelse av 24-nor-UDCA
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60326069D1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
WO2005003103A3 (en) 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
CY1110401T1 (el) Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
DE602004024992D1 (de) Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten
DE60234031D1 (de) Mittel zur behandlung allergischer augenerkrankungen
WO2007048034A3 (en) Use of androgens for the treatment of parkinson' s disease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1594833

Country of ref document: EP